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Abstract
Background: Speech-related problems are common in Parkinson’s disease (PD), but there is little evidence for the
effectiveness of standard speech and language therapy (SLT) or Lee Silverman Voice Treatment (LSVT LOUD®).
Methods: The PD COMM pilot was a three-arm, assessor-blinded, randomised controlled trial (RCT) of LSVT LOUD®,
SLT and no intervention (1:1:1 ratio) to assess the feasibility and to inform the design of a full-scale RCT. Non-demented
patients with idiopathic PD and speech problems and no SLT for speech problems in the past 2 years were eligible. LSVT
LOUD® is a standardised regime (16 sessions over 4 weeks). SLT comprised individualised content per local practice
(typically weekly sessions for 6–8 weeks). Outcomes included recruitment and retention, treatment adherence, and data
completeness. Outcome data collected at baseline, 3, 6, and 12 months included patient-reported voice and quality of
life measures, resource use, and assessor-rated speech recordings.
Results: Eighty-nine patients were randomised with 90% in the therapy groups and 100% in the control group
completing the trial. The response rate for Voice Handicap Index (VHI) in each arm was ≥ 90% at all time-points.
VHI was highly correlated with the other speech-related outcome measures. There was a trend to improvement
in VHI with LSVT LOUD® (difference at 3 months compared with control: − 12.5 points; 95% CI − 26.2, 1.2) and SLT
(difference at 3 months compared with control: − 9.8 points; 95% CI − 23.2, 3.7) which needs to be confirmed in
an adequately powered trial.
Conclusion: Randomisation to a three-arm trial of speech therapy including a no intervention control is feasible
and acceptable. Compliance with both interventions was good. VHI and other patient-reported outcomes were
relevant measures and provided data to inform the sample size for a substantive trial.
Trial registration: International Standard Randomised Controlled Trial Number Register: ISRCTN75223808.
registered 22 March 2012.
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Background
Speech problems affect 51–74% of patients with Parkinson’s
disease (PD). [1–3] Speech changes can occur in the early
stages of the disease and difficulty in communication can
lead to social isolation. In a UK survey of 125 people with
mainly early PD, Miller and colleagues [4] found only 4.2%
reported no changes to their speech or voice and 82% were
dissatisfied with how they spoke. For 10%, speech was their
main concern amongst all the changes experienced due to
PD and 38% placed speech in their top four concerns.
Drug therapy has only modest effects on prosodic
aspects of parkinsonian speech, so other therapeutic
measures such as speech and language therapy (SLT)
could play a role in treatment. [5] Conventional SLT is
tailored to individual patients’ needs and may include:
diaphragmatic breathing, pacing/rate control, word-
finding strategies, and voice/articulation exercises. [6]
One technique that has been used in PD is attention to
effort, where the speaker is asked to produce a loud
voice and focus their effort on attaining, monitoring,
and maintaining this. This technique was formalised in
an evidence-based commercially available programme
provided by the Lee Silverman Voice Treatment (LSVT
LOUD®) organisation from the late 1980s. [7] Several
studies [8–11] showed promising results of LSVT
LOUD® producing, not only louder voice, but also gains
in articulatory parameters which were sustained at
follow-up. Cochrane reviews have summarised the evi-
dence for the efficacy of various forms of SLT in PD, but
concluded that there was insufficient evidence to sup-
port the use of one form of SLT over another and rec-
ommended a large, methodologically sound randomised
controlled trial (RCT), with follow-up of at least
6 months and meaningful outcome measures. [12, 13]
The PD COMM pilot trial assessed the feasibility and
acceptability of a large-scale RCT to assess the clinical
and cost effectiveness of LSVT LOUD® versus standard
SLT versus no intervention in dysarthria associated with
PD. In accordance with guidance of the Medical Re-
search Council (MRC) for trials of complex interven-
tions [14] the following parameters were assessed: (1)
feasibility and acceptability of randomising PD patients
with problems of speech or voice to LSVT LOUD®, trad-
itional SLT interventions or no intervention control; (2)
patient eligibility, recruitment, and retention rates; (3)
numbers of sites and patients that need to be screened;
(4) time required to undertake a full-scale trial; (5) ac-
ceptability and adherence with LSVT LOUD®; (6) dose
and content of traditional SLT; (7) data completeness
and suitability of data collection methods; (8) assessment
of the most suitable primary outcome measure for the
full-scale trial and to obtain initial estimates to inform
the sample size calculation; and (9) pilot bespoke and
standard health economic evaluation questionnaires.
Methods
Study design
The PD COMM pilot trial protocol has been published.
[15] The trial was designed as a multicentre three-arm
parallel group randomised controlled pilot trial with
blinded assessor. It was sponsored by the University of
Birmingham, received ethical approval from the West
Midlands, Coventry and Warwick NHS Research Ethics
Committee (11/WM/0343), and local NHS R&D
approval at each site prior to the start of recruitment.
The trial was managed by the University of Birmingham
Clinical Trials Unit (BCTU). Due to the nature of the
intervention, therapists and patients were not blinded to
treatment allocation; however, assessors of the vocal
assessment outcome data were all blinded to treatment
allocation for the duration of the trial.
Patients
Eligibility criteria were idiopathic PD defined by the UK
Parkinson’s Disease Society Brain Bank Criteria; [16] and
presence of patient or carer-reported problems with
speech. [1] Exclusion criteria were dementia as defined
clinically by the physician; evidence of laryngeal path-
ology including vocal nodules, a history of vocal strain,
or previous laryngeal surgery as LSVT LOUD® is not
appropriate for all of this group; [9] received SLT for PD
speech-related problems in the past 2 years; and the
investigator thought that the patient did not definitely
require SLT in the short term.
Consent and randomisation
Potential patients who met the eligibility criteria were
approached in their normal outpatient appointments. If
interested, they were given a patient information sheet
and time to consider the trial and discuss it with friends
and family. Following consent, patients completed base-
line assessments prior to randomisation. For practical
reasons, baseline vocal assessments were allowed to be
performed after randomisation, but had to be completed
prior to the start of therapy.
After completing the baseline questionnaires, patients
were randomised in a 1:1:1 ratio to the three groups via
the trials unit telephone randomisation service. This se-
cure central randomisation service was available from
9 am to 5 pm weekdays and ensured the concealment of
treatment allocation. A computer-generated randomisa-
tion list was used. Patients and therapists were informed
of the treatment allocation, but assessors of the vocal
assessments remained blind to treatment allocation. If
allocated to an intervention arm, referral to the appro-
priate speech and language therapist occurred immedi-
ately following randomisation. All personal information
obtained for the study was held securely and treated as
strictly confidential.
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Interventions
Both SLT and LSVT LOUD® were delivered either in
community-based healthcare places or in outpatient
neurology units in the UK.
LSVT LOUD® was administered in four sessions per
week for 4 weeks (i.e. 16 sessions in total) by state regis-
tered speech and language therapists with certification
in Lee Silverman Voice Therapy and appropriate re-
fresher courses working within the NHS. Each session
lasted 50–60 min. In addition, patients were asked to
complete 5–10 min of home practise on treatment days
and up to 30 min of home practise on non-treatment
days. LSVT LOUD® comprises maximum effort non-
speech and speech drills. The non-speech drills include
production of sustained ‘ah’ phonation at a single pitch
and pitch glides (moving from modal pitch to high pitch
and modal pitch and going down on production of sus-
tained ‘ah’). These exercises are for improving vocal ef-
fort and loudness for translation into functional speech.
The speech drills utilise a hierarchy of speech tasks mov-
ing from single words through phrases and onto conver-
sational speech. Each step in this hierarchy puts
increased demands on the speaker and challenges the
speaker to maintain maximal speech production. It is
important to note the intervention incorporates retrain-
ing the sensory system to improve loudness.
SLT was administered as per local practice by state-
registered speech and language therapists and was
expected to typically involve one session of 45 min per
week for 6–8 weeks of varying content as determined by
patient need. Treatments could include exercises target-
ing respiration, phonation, articulation [17, 18], behav-
ioural strategies to reduce prosodic abnormality [19],
and the use of augmentative and alternative communica-
tion (AAC) strategies and therapeutic devices to improve
functional communication [20].
Those individuals allocated to the control group con-
tinued with their standard PD care. They were excluded
from receiving SLT input for at least 6 months post-
randomisation, unless their clinician deemed it to be
medically necessary. After 6 months, people in the con-
trol arm were eligible to be referred for therapy if
required.
Training on trial processes was provided for trial ther-
apists by the clinical trial team to ensure uniformity of
trial procedures. Therapists providing the interventions
completed intervention record forms at each session, as
used in previous complex intervention trials, [21] to
allow monitoring of intervention delivery.
Sample size
As this was a pilot study, no formal sample size calcula-
tion was performed. The study aimed to recruit at least
20 patients in each group, a total of at least 60 patients.
Outcomes
Data on various outcome measures were collected to
assess appropriate outcome measures to be used in a
large-scale trial: patient-reported measures-Voice
Handicap Index (VHI) [22], Parkinson’s Disease
Questionnaire-39 (PDQ-39) [23], voice-related quality
of life scale (V-RQoL) [24], Living with Dysarthria
questionnaire (LwD) [25], EuroQol (EQ-5D) [26, 27],
ICECAP capability measure for older people (ICECAP-O)
[28], and resource usage; therapist measures-vocal loud-
ness, comprehension assessments, and Assessment of
Intelligibility of Dysarthric Speech (AIDS) [29]; carer-
reported quality of life (Parkinson’s Disease Question-
naire–Carer, PDQ-Carer [30]); and adverse events. The
questionnaires used were all validated and widely used
tools. Data were collected before randomisation and 3, 6,
and 12 months after randomisation. The bespoke resource
usage questionnaire was assessed at 3, 6, and 12 months
for suitability in a definitive trial. This included questions
on health and social care resource use, employment and
time off work, and out of pocket costs incurred by
patients.
Following a risk assessment, it was agreed that this
was a low risk trial and that only vocal strain or abuse
were likely to be related to the interventions. Therefore,
targeted treatment-related adverse events and serious
adverse events such as vocal strain or abuse were
collected.
Data analyses
As this was a feasibility study, definitive comparisons of
the interventions were not undertaken. Feasibility mea-
sures and outcome data were therefore summarised de-
scriptively. Details on patient screening, recruitment and
retention, withdrawals and those lost to follow-up, along
with reasons for non-completion, and adherence were
summarised using a CONSORT diagram (objectives 1–
5). Adherence with LSVT LOUD was assessed as the
proportion of patients who completed the intervention
as per the protocol (objective 5). Information on the in-
terventions including the median number and mean
duration of sessions was summarised descriptively
(objectives 5 and 6). The percentage of forms
returned and level of data completeness at each time
point was tabulated (objective 7). Assessment of the
most suitable primary outcome measure for the full-scale
trial and which outcomes to retain in a substantive trial
included (1) an assessment of data completeness and (2)
correlation methods to identify which outcome measures
were closely correlated (objective 8). To help inform the
sample size calculation, the mean and standard deviation
for each outcome was summarised at each time point and
an exploratory analysis of differences between the arms
(LSVT LOUD® versus no intervention, SLT versus no
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intervention, and LSVT LOUD® versus SLT) was per-
formed, calculating the mean difference at each time point
and the mean change from baseline to 3, 6, and 12 months
alongside 95% confidence intervals (CI) (objective 8).
Missing values in PDQ-39 domain scores were imputed
using an expectation maximisation algorithm.[31, 32] As
is standard for phase III clinical trials, the pilot outcome
data were analysed using intention-to-treat methods with
patients analysed in the treatment group to which they
were randomised regardless of adherence to the interven-
tion or protocol. Statistical analysis was performed using
SAS version 9.4 software.
Results
Patient acceptability, screening, recruitment, and
retention (objectives 1–4)
Sites reported screening 2223 patients, with 89 patients
randomised into the PD COMM pilot trial from 12 centres
between May 2012 and March 2014. Data on the potential
participants screened showed variations in recruitment
methods: some centres screened PD clinic populations se-
quentially, whereas others recruited patients from therapist
services. The reasons patients were not entered into the
trial were no problems with speech or voice (n = 1406),
had SLT or likely to (n = 177), dementia (n = 176), too un-
well (n = 119), already in a trial (n = 92), very little English
(n = 21), and declined (n = 143). Therefore, the main rea-
son for non-entry into the trial was that the patient was
not eligible (79%). Only 6% of screened participants
declined the trial which suggests that the study was accept-
able to patients.
Thirty patients were randomised to LSVT LOUD®, 30
to SLT, and 29 to the control group, with 27 (90%), 27
(90%), and 29 (100%) completing the trial, respectively
(Fig. 1).
Treatment fidelity, adherence, and content
(objectives 5 and 6)
In the LSVT LOUD® group, 26 of 30 patients started
LSVT, with 22 (73%) completing LSVT as per proto-
col (Fig. 1). Seven patients randomised to LSVT
LOUD® either did not start (n = 3) or stopped therapy
early (i.e. did not complete 16 sessions; n = 4). The
four patients that stopped therapy received 1–3 ses-
sions. Three of these seven patients withdrew from
the trial citing the intensity and time commitment of
LSVT LOUD® as the reason for withdrawal (Fig. 1).
One patient randomised to SLT did not start therapy
for family reasons and then withdrew from the trial.
In the LSVT LOUD® group, 47% of patients had their
initial interview within 4 weeks of randomisation com-
pared to 57% in the standard SLT group. Delivery of the
intervention was good, with 96% in the LSVT LOUD®
arm and 97% in the SLT arm starting treatment within
3 months, and 86% in the LSVT LOUD® arm and 73% in
the SLT arm completing treatment within 3 months. In
the LSVT LOUD® group, patients had a median of 16
sessions lasting on average 61 min over 4.7 weeks. In the
SLT group, patients had a median of 6 sessions lasting
on average 54 min over 9.6 weeks.
Form return rates and data completeness (objective 7)
Data return rates were very good (> 90%). The combined
response rates for VHI was 99, 93, 95, and 94% at base-
line, 3, 6, and 12 months follow-up, respectively, and the
return rates were balanced across the arms. Completion
of the VHI forms was close to the planned time points,
and data completeness was good. Similar return rates
and levels of data completeness were seen across all the
other outcome measures. In the V-RQoL, one question
was not answered reliably (“I have trouble doing my job
or practising my profession”), so this questionnaire has
been dropped in the main trial.
Patient characteristics at randomisation
Patients entering the trial had a mean age of 67 years
(male 78%; body mass index 27 kg/m2). Mean disease
duration was 5.5 years with a baseline Hoehn and Yahr
stage ≤ 2.0 in 66%. The mean baseline levodopa dose
equivalent was 580 mg/day (Table 1). [33] Thirty-five
patients had a regular carer of which 29 (83%) consented
to enter the trial and complete the PDQ-Carer question-
naire (13 LSVT, 11 NHS, 5 control). Most carers were
female and spouses.
Assessment of outcome measures for the full-scale trial
(objective 8)
Correlations between the patient and therapist-assessed
outcomes were varied (Table 2; range − 0.58 to 0.02), but
patient-reported outcomes correlated well with each
other (r > 0.7). Interestingly, vocal loudness did not cor-
relate well with the patient-reported measures (r < 0.2).
In a survey of patients with PD from our Patient and
Public Involvement Group, we asked patients what was
more important to them: vocal loudness or ability to
communicate. The results showed that although vocal
loudness was important, it was only one aspect of a
complex problem which was also influenced by environ-
mental factors (e.g. dry mouth, stress levels), and that
patients preferred a more generic overall assessment of
voice problems.
Since VHI correlated best with therapist-assessed out-
comes and the PDQ-39 is a well-validated questionnaire
used in PD research, we investigated both the VHI total
score and PDQ-39 communication domain further as
possible primary outcome measures for the main trial.
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Fig. 1 Flow of patients through the trial
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Data to inform the sample size calculation (objective 8)
There was a − 12.5-point difference (95% CI − 26.2,
1.2) in the VHI total score at 3 months between
LSVT LOUD® and control group, and a difference of
− 9.8 points (95% CI − 23.2, 3.7) in the VHI total
score at 3 months between SLT and control group.
For the PDQ-39 communication score, at 3 months,
there was a 7.5-point difference (95% CI − 20.3, 5.2)
between the LSVT LOUD® and control group
(Table 3), and a 5.0-point difference (95% CI − 16.7
to 6.8) between the SLT and control groups. The VHI
total score and PDQ-39 communication domain data
at baseline, and 3, 6, and 12 months are shown in
Figs. 2 and 3.
The minimum clinically important change (MCIC) for
the communication domain of the PDQ-39 is 4.2 points
[34]. The mean baseline score was 33.8, assuming no de-
terioration in the control arm, the MCIC corresponds to
detecting a conservative 12% difference and a small ef-
fect size of 0.17 SD. The differences between LSVT
LOUD® and SLT versus control at 3 months were 7.5
and 5.0 points, respectively. Although these differences
are greater than the MCIC (4.2 points), they are close
enough to the MCIC to make it difficult to justify
powering a definitive study on a larger difference than
the MCIC. If we used the PDQ-39 communication as
our primary outcome, at 80% power and using α = 0.025
(to adjust for multiple comparisons), we would need to
recruit 2028 patients to detect a difference of 4.2 points
(the MCIC), which is unfeasible. The MCIC for VHI has
not been established for this cohort of patients. The dif-
ferences in VHI total score at 3 months between LSVT
LOUD® and SLT versus control were 12.5 and 9.8 points,
respectively. Assuming a difference of 10 points between
therapy groups and control, along with the upper stand-
ard deviation of 26.3, the effect size is moderate at 0.38
SD. Due to the nature and cost of the interventions, and
the trial primarily comparing intervention versus con-
trol, this justifies investigating a moderate effect size.
The VHI is also a questionnaire that specifically asks an
Table 1 Patient characteristics at randomisation
LSVT SLT Control
Number of patients randomised 30 30 29
Age (years) Mean (SD) 67 (8.4) 68 (10.3) 65 (7.5)
Gender Male (N, %) 23 (77%) 23 (77%) 23 (79%)
Body Mass Index (kg/m2) Mean (SD) 27.4 (4.3) 27.6 (4.8) 27.3 (4.2)
Duration of PD (years) Mean (SD) 6.1 (3.7) 5.6 (4.2) 4.9 (3.4)
Hoehn and Yahr stage ≤ 2.0 20 (67%) 16 (55%) 20 (77%)
2.5 5 (17%) 2 (7%) 5 (19%)
3.0 4 (13%) 9 (31%) 1 (4%)
≥ 4.0 1 (3%) 2 (7%) 0 (−)
Levodopa equivalent dose (mg/day)a Mean (SD) 695 (466.4) 533 (328.5) 502 (451.6)
aLevodopa equivalency formula from reference [33]
Table 2 Pearson correlation coefficients of participant and therapist-rated outcomes
Baseline 3 months
VHI–total score PDQ-39 communication V-RQoL LwD VHI PDQ-39 communication V-RQoL LwD
Participant-rated
VHI-total score 1.00 – – – 1.00 – – –
PDQ-39 communication 0.73 1.00 – – 0.74 1.00 – –
V-RQoL 0.86 0.76 1.00 – 0.90 0.77 1.00 –
LwD 0.77 0.73 0.78 1.00 0.78 0.75 0.79 1.00
Therapist-rated
AIDS words −0.64 −0.45 −0.46 −0.33 −0.53 −0.30 −0.31 −0.38
AIDS sentences −0.65 −0.43 −0.45 −0.35 −0.58 −0.34 −0.36 −0.35
Rainbow passage 0.17 0.15 0.16 0.08 −0.11 0.02 −0.15 −0.12
Cookie theft −0.10 0.03 0.03 −0.14 −0.14 −0.02 −0.12 −0.18
Vocal loudness −0.09 −0.15 −0.06 −0.12 −0.16 −0.10 −0.12 −0.18
VHI Voice Handicap Index, PDQ-39 Parkinson’s Disease Questionnaire-39, V-RQoL voice-related quality of life score, LwD Living with Dysarthria score
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individual to describe their voice and the effects of their
voice on their life. We therefore chose the VHI total
score as the primary outcome measure for the substan-
tive trial. To detect a 10-point difference in VHI total
score at 3 months (upper SD 26.3; 80% power; α = 0.025)
requires 399 patients (133 per group).
Safety
There were no adverse events or serious adverse events
reported in the trial.
Pilot health economic evaluation questionnaires
(objective 9)
A substantive trial should also contain a full economic
evaluation to estimate the incremental cost-effectiveness
of the LSVT LOUD® intervention versus SLT and no
intervention. Piloting the bespoke resource use question-
naire demonstrated that it was suitable, as the comple-
tion rate was good. The EQ-5D and the ICECAP-O
were confirmed to be suitable economic outcome mea-
sures, to measure both health-related quality of life and
broader aspects of capability.
Table 3 Results of participant-rated and carer-rated outcomes
Baseline 3 Months
LSVT NHS Control LSVT NHS Control LSVT vs. control NHS vs. control
VHI total score N = 26
42 (20.2)
N = 28
42 (25.5)
N = 26
42 (21.0)
N = 22
33 (22.4)
N = 22
36 (21.2)
N = 28
46 (25.1)
− 12.5 (− 26.2 to 1.2) − 9.8 (− 23.2 to 3.7)
PDQ-39 communication domain N = 29
35 (23.3)
N = 30
33 (21.5)
N = 29
33 (19.5)
N = 26
27 (22.9)
N = 27
30 (19.4)
N = 29
35 (24.0)
− 7.5 (− 20.3 to 5.2) − 5.0 (− 16.7 to 6.8)
PDQ-39 summary index N = 29
32 (15.5)
N = 30
28 (13.8)
N = 29
26 (14.1)
N = 26
29 (17.5)
N = 27
27 (13.8)
N = 29
29 (16.3)
− 0.2 (− 9.3 to 9.0) − 2.1 (− 10.2 to 6.0)
V-RQoL N = 27
20 (8.9)
N = 25
20 (8.3)
N = 25
21 (7.1)
N = 21
18 (7.8)
N = 24
19 (5.6)
N = 28
22 (8.0)
− 3.5 (− 8.1 to 1.1) − 3.2 (− 7.1 to 0.7)
LwD N = 27
28 (16.2)
N = 27
32 (21.9)
N = 26
27 (20.7)
N = 25
24 (21.6)
N = 24
28 (17.1)
N = 25
29 (20.4)
− 5.6 (− 17.6 to 6.3) − 1.9 (− 12.8 to 8.9)
EQ-5D QoL score N = 29
0.59 (0.30)
N = 30
0.64 (0.23)
N = 29
0.72 (0.18)
N = 26
0.60 (0.27)
N = 27
0.70 (0.20)
N = 28
0.60 (0.29)
0.004 (− 0.15 to 0.16) 0.11 (− 0.03 to 0.25)
PDQ-Carer summary index N = 11
27 (19.7)
N = 11
26 (20.9)
N = 3
15 (18.2)
N = 11
32 (22.9)
N = 7
21 (13.4)
N = 4
18 (17.8)
15.8 (− 15.7 to 47.3) 5.9 (− 19.1 to 30.9)
Mean difference (95% CI) for comparisons
VHI ranges from 0 to 120; PDQ-39 ranges from 0 to 100; V-RQoL ranges from 10 to 50; LwD ranges from 0 to 90; PDQ-Carer ranges from 0 to 100, where low score
is good. Negative difference favours treatment
EQ-5D ranges from − 0.59 to 1, where high score is good. Positive difference favours treatment
Fig. 2 VHI total score over time
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Discussion
The results of the PD COMM pilot study have shown
that a large-scale trial to evaluate the efficacy and
cost-effectiveness of Lee Silverman Voice Treatment
versus standard NHS speech and language therapy
versus control for communication problems in PD is
both acceptable and feasible. The UK Medical
Research Council advises that in feasibility trials of
complex interventions a number of parameters should
be assessed which we discuss in the following para-
graphs. [14]
We originally aimed to recruit 60 patients from four
centres over 18 months, but expanded to 12 centres
because of slow recruitment, eventually recruiting 89 pa-
tients over 23 months.
The main reasons potential participants did not take
part in the study were lack of speech problems (66%),
dementia (8%), and declined consent (7%). The discrep-
ancy between the estimates of prevalence of problems
and those in the recruiting NHS clinics is interesting
and important for planning the full trial, however, it is
unexplained at present.
Randomisation to a no treatment arm was acceptable
to patients and clinicians, and retention rates during the
whole trial were high at around 90%. There was a con-
cern that the high intensity of LSVT LOUD® might lead
to a high withdrawal rate. A number of patients decided
not to enter the trial because of the intensity of LSVT
LOUD® which did affect recruitment rates. Of those who
entered the trial, seven in the LSVT LOUD® arm either
did not start therapy or stopped LSVT LOUD® early,
with three of these patients withdrawing from the trial.
This compares with only one patient in the SLT arm
who did not start therapy.
Our study has demonstrated the ability to successfully
deliver two distinct complex SLT interventions for dys-
arthria associated with PD which differed in session
length, time to intervention, overall dose of therapy, and
intervention duration. High intensity SLT therapy is not
tolerated by all patients, and the results for trials
employing such approaches amongst other patient
groups have been confounded by significantly higher
dropout rates (than seen in our study) from the high in-
tensity groups [35]. Intervention delivery will be a chal-
lenging issue during the substantive trial, particularly
given the difficult financial situation within the National
Health Service. However, delivery of the intervention in
the pilot was good, with most patients starting and com-
pleting the intervention within 3 months of randomisa-
tion. It was noted that there was a slight difference in
the number of patients completing treatment by
3 months (86% in the LSVT LOUD® group compared
with 73% in the SLT group); we will monitor this closely
within the main trial.
A battery of patient and carer reported assessments
were employed in the study to evaluate the feasibility,
acceptability, sensitivity, and correlation of outcome
measures. Data return and completeness for all outcome
measures at each time point was excellent. Correlations
between the patient and therapist-assessed outcomes
were varied, but patient-reported outcomes correlated
well with each other (r > 0.7). Vocal loudness did not
correlate well with patient-reported measures (r < 0.2).
Previous trials have used vocal loudness as the primary
Fig. 3 PDQ-39 communication domain over time
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outcome measure, but it is not clear whether this cap-
tures what is important to patients in terms of commu-
nication. Our survey of a number of patients with PD
showed that patients preferred and wanted a more gen-
eric overall assessment of voice problems.
Since the VHI correlated best with the therapist-
assessed outcomes and the PDQ-39 is a well-validated
questionnaire used in PD research, we investigated both
the VHI total score and PDQ-39 communication domain
as possible primary outcome measures for the main trial.
The sample sizes for a full-scale trial using these out-
comes (with 80% power, α = 0.025 (to adjust for multiple
comparisons)) were 2028 patients with the PDQ-39
communication domain and 399 patients with the VHI
total score. A 2000 patient trial was not feasible, and
based on the VHI asking an individual to describe their
voice and the effects of their voice on their life, which
came out as important from our patient survey, the VHI
total score was chosen as the primary outcome. To de-
tect a 10-point difference in VHI total score at 3 months
(upper SD 26.3; 80% power; α = 0.025) will require 399
patients (133 per arm). To allow for 10% drop out, a
total of 450 patients (150 per arm) will be recruited.
From the feasibility study, six patients can be recruited
per site per year, so with 40 sites, 450 patients can be re-
cruited in just under 2 years.
Conclusions
PD COMM pilot is the largest trial to date of SLT in
PD. The three trials in the Cochrane review included a
total of only 63 patients [13] and the most recent trial of
LSVT LOUD® LOUD and ARTIC versus no therapy in-
cluded only 64 patients. [36] The PD COMM pilot trial
demonstrated that both LSVT LOUD® and SLT may be
effective in improving communication in PD, although
this needs to be confirmed in an adequately powered
trial. Our study established that such a substantive trial
is both feasible and acceptable to PD patients and thera-
pists treating their communication problems. A large-
scale trial (PD COMM) is now underway in the United
Kingdom.
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